Zeo ScientifiX, Inc.
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. Its lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, osteoarth… Read more
Zeo ScientifiX, Inc. (ZEOX) - Total Assets
Latest total assets as of October 2025: $1.53 Million USD
Based on the latest financial reports, Zeo ScientifiX, Inc. (ZEOX) holds total assets worth $1.53 Million USD as of October 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Zeo ScientifiX, Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Zeo ScientifiX, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Zeo ScientifiX, Inc. - Asset Composition Analysis
Current Asset Composition (October 2025)
Zeo ScientifiX, Inc.'s total assets of $1.53 Million consist of 62.7% current assets and 37.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $35.00K | 2.3% |
| Inventory | $423.00K | 27.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Zeo ScientifiX, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zeo ScientifiX, Inc.'s current assets represent 62.7% of total assets in 2025, a decrease from 63.4% in 2020.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2025, down from 44.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 27.7% of total assets.
Zeo ScientifiX, Inc. Competitors by Total Assets
Key competitors of Zeo ScientifiX, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Zeo ScientifiX, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Zeo ScientifiX, Inc. generates 3.40x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Zeo ScientifiX, Inc. is currently not profitable relative to its asset base.
Zeo ScientifiX, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.33 | 0.35 | 0.54 |
| Quick Ratio | 0.19 | 0.28 | 0.46 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.92 Million | $ -2.12 Million | $ -1.51 Million |
Zeo ScientifiX, Inc. - Advanced Valuation Insights
This section examines the relationship between Zeo ScientifiX, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 6.94 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | $1.53 Million |
| Market Capitalization | $10.59 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zeo ScientifiX, Inc.'s assets at a significant premium ( 6.94x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Zeo ScientifiX, Inc.'s assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zeo ScientifiX, Inc. (2020–2025)
The table below shows the annual total assets of Zeo ScientifiX, Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $1.53 Million | -7.06% |
| 2024-10-31 | $1.64 Million | -40.95% |
| 2023-10-31 | $2.78 Million | -55.13% |
| 2022-10-31 | $6.20 Million | +220.79% |
| 2021-10-31 | $1.93 Million | +44.88% |
| 2020-10-31 | $1.33 Million | -- |